Patient characteristics (N = 216)
| Characteristic . | n (%) . |
|---|---|
| Patient age at onset of second-line treatment, y | |
| Median | 41 |
| Range | 1-76 |
| <12 y | 38 (18) |
| 12-17 | 17 (8) |
| 18-39 | 47 (22) |
| 40-59 | 70 (32) |
| | 44 (20) |
| Patient sex | |
| Female | 97 (45) |
| Donor-patient sex combination | |
| Female to male | 46 (21) |
| Diagnosis at transplant | |
| Myeloid malignancy | 115 (53) |
| Lymphoid malignancy | 66 (31) |
| Other/nonmalignant | 35 (16) |
| Disease risk at transplant* | |
| Low risk | 7 (3) |
| Standard risk | 179 (83) |
| High risk | 30 (14) |
| Conditioning regimen | |
| High dose without total body irradiation | 65 (30) |
| High dose with total body irradiation | 60 (28) |
| Reduced intensity | 91 (42) |
| Graft source | |
| Bone marrow | 53 (25) |
| PBSCs | 130 (60) |
| Cord blood | 33 (15) |
| Donor and HLA type | |
| HLA-matched related | 33 (15) |
| HLA-matched unrelated | 100 (46) |
| HLA antigen or allele-mismatched related | 12 (6) |
| HLA antigen or allele-mismatched unrelated | 71 (33) |
| GVHD prophylaxis | |
| Cyclosporine or tacrolimus | 208 (96) |
| Methotrexate or mycophenolate mofetil | 204 (94) |
| Sirolimus | 5 (2) |
| Posttransplant cyclophosphamide | 19 (9) |
| HCT-CI before transplantation | |
| | 107 (50) |
| Prior allogeneic transplantation | 35 (16) |
| Characteristic . | n (%) . |
|---|---|
| Patient age at onset of second-line treatment, y | |
| Median | 41 |
| Range | 1-76 |
| <12 y | 38 (18) |
| 12-17 | 17 (8) |
| 18-39 | 47 (22) |
| 40-59 | 70 (32) |
| | 44 (20) |
| Patient sex | |
| Female | 97 (45) |
| Donor-patient sex combination | |
| Female to male | 46 (21) |
| Diagnosis at transplant | |
| Myeloid malignancy | 115 (53) |
| Lymphoid malignancy | 66 (31) |
| Other/nonmalignant | 35 (16) |
| Disease risk at transplant* | |
| Low risk | 7 (3) |
| Standard risk | 179 (83) |
| High risk | 30 (14) |
| Conditioning regimen | |
| High dose without total body irradiation | 65 (30) |
| High dose with total body irradiation | 60 (28) |
| Reduced intensity | 91 (42) |
| Graft source | |
| Bone marrow | 53 (25) |
| PBSCs | 130 (60) |
| Cord blood | 33 (15) |
| Donor and HLA type | |
| HLA-matched related | 33 (15) |
| HLA-matched unrelated | 100 (46) |
| HLA antigen or allele-mismatched related | 12 (6) |
| HLA antigen or allele-mismatched unrelated | 71 (33) |
| GVHD prophylaxis | |
| Cyclosporine or tacrolimus | 208 (96) |
| Methotrexate or mycophenolate mofetil | 204 (94) |
| Sirolimus | 5 (2) |
| Posttransplant cyclophosphamide | 19 (9) |
| HCT-CI before transplantation | |
| | 107 (50) |
| Prior allogeneic transplantation | 35 (16) |
Low-risk diseases included chronic myeloid leukemia (CML) in chronic phase; high-risk diseases included acute leukemia not in remission, CML in blast crisis, refractory anemia with excess blasts (RAEB), or RAEB in transformation and myeloma; all other diseases and stages were categorized as standard risk.